Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 1
2(50.0%)
4Total
N/A(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01941316Phase 1Completed

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

Role: collaborator

NCT02227654Not ApplicableCompleted

Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors

Role: collaborator

NCT00004062Phase 1Completed

Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer

Role: lead

NCT00404365Not ApplicableCompleted

Depression Screening in Patients With Lung Cancer

Role: collaborator

All 4 trials loaded